Tapering biologic DMARDs in rheumatoid arthritis

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Biologic therapies have transformed rheumatoid arthritis (RA) treatment, enabling sustained clinical responses.
• However, biologics present challenges including cost, convenience, and potential side effects.
• Clinical uncertainty exists regarding the tapering of biologic therapy in RA patients achieving tight disease control.

Purpose of the Study:

• To summarize current evidence on biologic tapering in rheumatoid arthritis (RA).
• To outline real-world outcomes and contextual factors for therapy de-escalation.
• To review international guidelines and patient perspectives on biologic therapy de-escalation.

Main Methods:

• Literature review of current evidence on biologic tapering in RA.
• Analysis of real-world outcomes data for therapy de-escalation.
• Synthesis of international rheumatology guidelines and patient perspectives.

Main Results:

• Recent evidence indicates sustained remission or low disease activity is achievable with biologic dose reduction.
• Predictors for successful biologic tapering in RA are beginning to be identified.
• International guidelines show a lack of consensus on the specifics of biologic therapy de-escalation.

Conclusions:

• Biologic dose reduction, not outright discontinuation, may be a viable strategy for maintaining low disease activity in RA.
• Further research is needed to refine predictors and optimize strategies for biologic tapering in RA.
• Considering cost-effectiveness and patient preferences is crucial when de-escalating RA therapy.